(Total Views: 764)
Posted On: 05/08/2025 1:09:00 PM
Post# of 152747
Great post from IHUB.. easy explanation to many about our drug ..
I think this original post from Tiny was on Redid
******************************
5.95akadawson-m
Re: docj post# 235157
Thursday, May 08, 2025 12:41:28 PM
Post# of 235158 Go
I'M GOING TO APPEAL TO ALL WHO KNOW HOW TO READ & FORMULATE A VERY SIMPLE ANSWER:
Trodelvy Got $21B for 0.85%.
This Penny Stock (CYDY) Just Hit 17.8% as a final result.
Trodelvy — FDA-approved, $21 BILLION buyout — is considered the best treatment available for aggressive breast cancer.
Here’s what that $21B gets you:
2 out of 235 women lived past 30 months
That’s 0.85%
Both are now gone ????
And the patients in that trial?
✅ Carefully selected
✅ No brain metastasis
✅ Early in their treatment journey
???? That’s what Big Pharma calls a “win.”
???? That’s what Wall Street pays billions for.
???? Now here’s what a penny stock just did:
CytoDyn ($CYDY) just dropped a new clinical update — not hype, not theory, real data — and here’s what it shows:
5 out of 28 women are still alive
Over 4 years later
4 of them are completely cancer-free
✅ Not managing it
✅ Not delaying it
✅ Gone. NED. No. Evidence. of. Disease.
And these weren’t cherry-picked.
These were:
Women who had already failed 3, 4, even 5 treatments
Some had cancer in the brain ???? — the kind of diagnosis usually measured in weeks, not years
Leronlimab was their last shot.
And it worked. ????
???? Let’s Do the Only Math That Matters:
Trodelvy: 2 / 235 = 0.85%
Leronlimab: 5 / 28 = 17.8%
? And 4 of those 5 are cancer-free
???? So Ask Yourself:
Would you rather back 0.85%… or 17.8%?
Would you rather bet on the best-case patients… or the ones medicine already gave up on?
This isn’t a toss-up.
This isn’t a maybe.
This is the most one-sided stat sheet you’ve never seen on CNBC.
???? So Why Isn’t Everyone Talking About This?
Because CytoDyn trades under $1
Because the abstract just dropped
Because no one expects miracles from the underdog
But now you know.
???? What’s Coming Next Week:
May 15 — the full data drop
? Full analysis
? Mechanism of Action
? Patient breakdown
? FDA pathway?
? Partner?
? Catalyst?
???? If you're reading this and not loading the boat...
I don’t know what to tell you.
If 0.85% was worth $21 billion…
What’s 17.8% — in the sickest patients — worth?
Anyone ever ride the "Cyclone" at Coney Island? Here's your chance to buy CYDY's Leronlimab for 33 c
I think this original post from Tiny was on Redid
******************************
5.95akadawson-m
Re: docj post# 235157
Thursday, May 08, 2025 12:41:28 PM
Post# of 235158 Go
I'M GOING TO APPEAL TO ALL WHO KNOW HOW TO READ & FORMULATE A VERY SIMPLE ANSWER:
Trodelvy Got $21B for 0.85%.
This Penny Stock (CYDY) Just Hit 17.8% as a final result.
Trodelvy — FDA-approved, $21 BILLION buyout — is considered the best treatment available for aggressive breast cancer.
Here’s what that $21B gets you:
2 out of 235 women lived past 30 months
That’s 0.85%
Both are now gone ????
And the patients in that trial?
✅ Carefully selected
✅ No brain metastasis
✅ Early in their treatment journey
???? That’s what Big Pharma calls a “win.”
???? That’s what Wall Street pays billions for.
???? Now here’s what a penny stock just did:
CytoDyn ($CYDY) just dropped a new clinical update — not hype, not theory, real data — and here’s what it shows:
5 out of 28 women are still alive
Over 4 years later
4 of them are completely cancer-free
✅ Not managing it
✅ Not delaying it
✅ Gone. NED. No. Evidence. of. Disease.
And these weren’t cherry-picked.
These were:
Women who had already failed 3, 4, even 5 treatments
Some had cancer in the brain ???? — the kind of diagnosis usually measured in weeks, not years
Leronlimab was their last shot.
And it worked. ????
???? Let’s Do the Only Math That Matters:
Trodelvy: 2 / 235 = 0.85%
Leronlimab: 5 / 28 = 17.8%
? And 4 of those 5 are cancer-free
???? So Ask Yourself:
Would you rather back 0.85%… or 17.8%?
Would you rather bet on the best-case patients… or the ones medicine already gave up on?
This isn’t a toss-up.
This isn’t a maybe.
This is the most one-sided stat sheet you’ve never seen on CNBC.
???? So Why Isn’t Everyone Talking About This?
Because CytoDyn trades under $1
Because the abstract just dropped
Because no one expects miracles from the underdog
But now you know.
???? What’s Coming Next Week:
May 15 — the full data drop
? Full analysis
? Mechanism of Action
? Patient breakdown
? FDA pathway?
? Partner?
? Catalyst?
???? If you're reading this and not loading the boat...
I don’t know what to tell you.
If 0.85% was worth $21 billion…
What’s 17.8% — in the sickest patients — worth?
Anyone ever ride the "Cyclone" at Coney Island? Here's your chance to buy CYDY's Leronlimab for 33 c
(26)
(0)Scroll down for more posts ▼
